Domov › Burkittov limfom › Illinois › Chicago

Klinične študije za Burkittov limfom v Chicago, IL

14 študij za Burkittov limfom išče udeležence na lokacijah v Chicago in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 3

Northwestern University, Chicago
Rush MD Anderson Cancer Center, Chicago
University of Illinois, Chicago
in še 1

Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Blinatumomab Consolidation in Real World

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Northwestern University, Chicago
The University of Chicago, Chicago

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 2

Northwestern University, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Vključevanje udeležencevFaza 2

Lurie Children's Hospital-Chicago, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Vključevanje udeležencevFaza 3

Lurie Children's Hospital-Chicago, Chicago
University of Illinois, Chicago
University of Chicago Comprehensive Cancer Center, Chicago

365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Vključevanje udeležencevFaza 2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Vključevanje udeležencevFaza 1/2

Research Site, Chicago

Starost 12 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 1/2

Research Site, Chicago

Starost 12 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Vključevanje udeležencevFaza 2

University of Chicago Comprehensive Cancer Center, Chicago

Starost 18–54 · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Vključevanje udeležencevFaza 1

University of Chicago Comprehensive Cancer Center, Chicago

Starost 18 in več · Vsi spoli · Posodobljeno 4. nov. 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Vključevanje udeležencevFaza 1/2

University of Chicago, Chicago

Starost 15–50 · Vsi spoli · Posodobljeno 9. sep. 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Vključevanje udeležencev

University of Chicago Medicine Comprehensive Cancer Center, Chicago

Starost 18–50 · Vsi spoli · Posodobljeno 19. jun. 2025 · NCT06785324

Študije za Burkittov limfom v drugih mestih

Druge študije v Chicago

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.